GATEWAY: a EUROSTARS 4 application for a gut-entheseal organ-on-chip platform
P3 Therapeutics and its European partners have applied to EUROSTARS 4 with project 12259-GATEWAY: a 2D and 3D humanised gut-entheseal organ-on-chip platform for testing a new class of anti-inflammatory small chemical molecules.
We have applied to the EUROSTARS 4 programme with project 12259-GATEWAY — “Gut-enthesis Axis Therapeutic Evaluation Workflow for multi-omics Analysis Yielding therapeutics and biomarkers”: a 2D and 3D humanised gut-entheseal organ-on-chip platform for testing a new class of anti-inflammatory small chemical molecules.
The consortium
- P3 Therapeutics — Croatia (coordinator)
- LBMC — Latvia (Ralf Bulks)
- University of Latvia — Latvia (Una Rekstina, Vadims Parfejevs)
- CubaseBio — Sweden (Malte Kuenemund, Julian Asbby)
- Protavio — Greece (Exarchos Kanelis)
- GrantMinded — Netherlands (Tom van Tilborg, Gido Akse), grant consultants
If funded, we will use this state-of-the-art platform to study mechanisms of action, pharmacokinetics and pharmacodynamics of our SCMs, as well as for compound biomarker development — the biomarker-driven, organ-on-chip route to new approach methodology (NAM) modelling described on the Science page.